礼来 2026年季度报告

Quarterly Report Pursuant to Section13 or 15(d) of theSecurities Exchange Act of 1934For the quarterly period ended March31, 2026COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) 35-0470950(I.R.S. EmployerIdentification No.) Lilly Corporate Center, Indianapolis, Indiana 46285(Address and zip code of principal executive offices)Registrant's telephone number, including area code (317)276-2000 Securities registered pursuant to Section12(b) of the Exchange Act: Indicate by check mark whether the Registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)has been subject to such filingrequirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growthcompany" in Rule 12b-2 of the Exchange Act. Acceleratedfiler☐Smaller reporting company☐Emerging growth company☐ Large accelerated filer☒Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒The number of shares of common stock outstanding as of April27, 2026: 941,741,406 Eli Lilly and CompanyForm 10-QFor the Quarter Ended March31, 2026Table of Contents PART I. Financial Information Financial StatementsConsolidated Condensed Statements of OperationsConsolidated Condensed Statements of Comprehensive IncomeConsolidated Condensed Balance SheetsConsolidated Condensed Statements of Cash FlowsNotes to Consolidated Condensed Financial StatementsManagement's Discussion and Analysis of Results of Operations andFinancial ConditionExecutive OverviewResults of OperationsFinancial Condition and LiquidityCritical Accounting EstimatesAvailable Information on our WebsiteQuantitative and Qualitative Disclosures About Market RiskControls and Procedures Item 1. Item 2. Item 3.Item 4. PART II. Other Information Legal ProceedingsRisk FactorsUnregistered Sales of Equity Securities and Use of ProceedsOther InformationExhibits Item 1.Item 1A.Item 2.Item 5.Item 6. Signatures Forward-Looking Statements This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements withinthe meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934(Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, andgenerally can be identified by the use of words such as "may," "could," "aim," "seek," "believe," "will," "expect," "project,""estimate," "intend," "target," "anticipate," "plan," "continue," or similar expressions or future or conditional verbs. Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ fromthose expressed in forward-looking statements. Forward-looking statements are based on management's current plansand expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurancethat any expectation or belief will result or will be achieved or accomplished. Investors therefore should not place unduereliance on forward-looking statements. The following include some but not all of the factors that could cause actualresults or events to differ from those anticipated: •the significant costs and uncertainties in the pharmaceutical research and development process, including withrespect to the timing and process of obtaining regulatory approvals and the ability of the company's clinical trials tomeet expectations; •the impact and uncertain outcome of acquisitions and business development transactions and related costs;•intense competition affecting our products, pipeline, or industry;•market uptake of launched products and indications;•continued pricing pressures and the impact of actions of governmental and private actors affecting pricing of,reimbursement f